The purpose of this study is to compare diagnostic performance of Prostate Imaging Reporting and Data System (PI-RADS) version (v) 2.1 and 2.0 for detection of Gleason Score (GS) ≥ 7 prostate cancer on MRI. Three experienced radiologists provided PI-RADS v2.0 scores and at least 12 months later v2.1 scores on lesions in 333 prostate MRI examinations acquired between 2012 and 2015. Diagnostic performance was assessed retrospectively by using MRI/transrectal ultrasound fusion biopsy and 10-core systematic biopsy as the reference. From a total of 359 lesions, GS ≥ 7 tumor was present in 135 lesions (37.60%). Area under the ROC curve (AUC) revealed slightly lower values for peripheral zone (PZ) and transition zone (TZ) scoring in v2.1, but these differences did not reach statistical significance. A significant number of score 2 lesions in the TZ were downgraded to score 1 in v2.1 showing 0% GS ≥ 7 tumor (0/11). The newly introduced diffusion-weighted imaging (DWI) upgrading rule in v2.1 was applied in 6 lesions from a total of 143 TZ lesions (4.2%). In summary, PI-RADS v2.1 showed no statistically significant differences in overall diagnostic performance of TZ and PZ scoring compared to v2.0. Downgraded BPH nodules showed favorable cancer frequencies. The new DWI upgrading rule for TZ lesions was applied in only few cases.
Lymphatic spread determines treatment decisions in prostate cancer (PCa) patients. 68Ga-PSMA-PET/ ct can be performed, although cost remains high and availability is limited. therefore, computed tomography (ct) continues to be the most used modality for pca staging. We assessed if convolutional neural networks (CNNs) can be trained to determine 68Ga-PSMA-PET/CT-lymph node status from CT alone. In 549 patients with 68Ga-PSMA PET/CT imaging, 2616 lymph nodes were segmented. Using PET as a reference standard, three CNNs were trained. Training sets balanced for infiltration status, lymph node location and additionally, masked images, were used for training. cnns were evaluated using a separate test set and performance was compared to radiologists' assessments and random forest classifiers. Heatmaps maps were used to identify the performance determining image regions. The CNNs performed with an Area-Under-the-Curve of 0.95 (status balanced) and 0.86 (location balanced, masked), compared to an AUC of 0.81 of experienced radiologists. Interestingly, CNNs used anatomical surroundings to increase their performance, "learning" the infiltration probabilities of anatomical locations. in conclusion, cnns have the potential to build a well performing ct-based biomarker for lymph node metastases in PCa, with different types of class balancing strongly affecting cnn performance. Prostate cancer (PCa) is the most common malignant cancer in men worldwide, and the second most common cause of cancer related death in men 1. Patients with intermediate or high-risk PCa undergo regular staging examinations in order to determine if the tumor has spread beyond the prostate. As treatment success is highly dependent on the presence of systemic spread 2,3 , staging procedures with high sensitivity and specificity are necessary. Standard of care imaging for PCa staging typically includes contrast-enhanced computed tomography (CT) and Technetium-99m-methylene diphosphonate bone scans 4,5. Despite the continued recommendation of CT in staging, it has been shown that predicting lymph node infiltration (LNI) with CT scans is not very reliable 6,7 , with one study reporting a sensitivity and specificity of only 42% and 82% 8. This low performance is most likely due to the limited morphological criteria used to define a lymph node as positive for infiltration, with size being the most relevant 9. A threshold of 8-10 mm is often used despite the fact that 80% of lymph node metastases are less than 8 mm in the short axis 10. Further criteria, such as status of hilum fat, nodal shape, and enhancement characteristics are used to aid diagnosis, but it remains difficult to exclude LNI in large benign hyperplastic nodes or detect it in small nodes below the size threshold 11. In 2012 imaging agents binding to Prostate Specific Membrane Antigen (PSMA) were introduced, leading to the development of PSMA PET/CT 8. PSMA, an integral membrane glycoprotein expressed 100-1000 fold on membranes of PCa cells compared to prostate cells, has been shown to correlate ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.